Drug Pipeline

Anti-PD-1 monoclonal antibody Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
5
Recruiting
5
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-14 NCT07365592
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC		 Recruitment opened
Active Studies by Phase
Phase 2
1
Phase 1/2
3
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT05182957 Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory… Relapsed/Refractory Peripheral T-cell Lymphoma Recruiting
Phase 1/2
NCT06425926 Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors Melanoma Stage IV Recruiting
NCT07365592 Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC Colorectal Cancer Recruiting
NCT05774275 The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized… High-Risk Localized Soft Tissue Sarcoma Recruiting
Phase 1
NCT07090148 Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC Prostate Cancer Patients Recruiting
Sponsors Running Anti-PD-1 monoclonal antibody Trials
The First Affiliated Hospital of Soochow University (1) Fudan University (1) Georgiamune Inc (1) University of Wisconsin, Madison (1) Second Affiliated Hospital, School of Medicine, Zhejiang University (1)
Disease Areas
Sarcoma (1) Melanoma (1) Prostate Cancer (1) Colorectal Cancer (1)
Get alerts when Anti-PD-1 monoclonal antibody trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free